Abstract:Background: Accumulating evidence suggests that regulated cell death, such as pyroptosis, apoptosis, and necroptosis, is deeply involved in the pathogenesis of psoriasis. As a newly recognized form of systematic cell death, PANoptosis is involved in a variety of inflammatory disorders through amplifying inflammatory and immune cascades, but its role in psoriasis remains elusive. Objectives: To reveal the role of PANoptosis in psoriasis for a potential therapeutic strategy. Methods: Multitranscriptomic analysis and experimental validation were used to identify PANoptosis signaling in psoriasis. RNA-seq and scRNA-seq analyses were performed to establish a PANoptosis-mediated immune response in psoriasis, which revealed hub genes through WGCNA and predicted disulfiram as a potential drug. The effect and mechanism of disulfiram were verified in imiquimod (IMQ)-induced psoriasis. Results: Here, we found a highlighted PANoptosis signature in psoriasis patients through multitranscriptomic analysis and experimental validation. Based on this, two distinct PANoptosis patterns (non/high) were identified, which were the options for clinical classification. The high-PANoptosis-related group had a higher response rate to immune cell infiltration (such as M1 macrophages and keratinocytes). Subsequently, WGCNA showed the hub genes (e.g., S100A12, CYCS, NOD2, STAT1, HSPA4, AIM2, MAPK7), which were significantly associated with clinical phenotype, PANoptosis signature, and identified immune response in psoriasis. Finally, we explored disulfiram (DSF) as a candidate drug for psoriasis through network pharmacology, which ameliorated IMQ-mediated psoriatic symptoms through antipyroptosis-mediated inflammation and enhanced apoptotic progression. By analyzing the specific ligand-receptor interaction pairs within and between cell lineages, we speculated that DSF might exert its effects by targeting keratinocytes directly or targeting M1 macrophages to downregulate the proliferation of keratinocytes. Conclusions: PANoptosis with its mediated immune cell infiltration provides a roadmap for research on the pathogenesis and therapeutic strategies of psoriasis.

Progress on Correlation Studies of Psoriasis and PD-1

Research progress of anti-PD-1 / PD-L1 immunotherapy biomarkers

Advances in pathogenesis and nanoparticles (NPs)-mediated treatment of psoriasis

PD-1 regulation in immune homeostasis and immunotherapy

Exploration of the underlying comorbidity mechanism in psoriasis and periodontitis: a bioinformatics analysis (vol 160, 7, 2023)

Exploration of the underlying comorbidity mechanism in psoriasis and periodontitis: a bioinformatics analysis

The role of PD-1 signaling in health and immune-related diseases

Correlation between PD-1 and sPD-L1 expression levels in peripheral blood of DLBCL patients and their clinicopathological characteristics

PD-1 and PD-1 ligands: from discovery to clinical application

PANoptosis signaling enables broad immune response in psoriasis: From pathogenesis to new therapeutic strategies

PD-1/PD-L1 pathway: current researches in cancer.

Signaling pathways and targeted therapies for psoriasis

The PD-1/PD-L pathway in rheumatic diseases

Correlation between PD-1/PD-L1 expression and polarization in tumor-associated macrophages: A key player in tumor immunotherapy

Novel insights into immune checkpoints in psoriasis and atopic dermatitis: From expression and function to treatments

PD-L1 expression on peripheral T-cells and association with coronary heart disease patients: A protocol for systematic reviews and meta-analysis

PD-1/PD-L Axis in Neuroinflammation: New Insights

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations

Exploring the role of programmed cell death protein 1 and its ligand 1 in eye diseases

Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy

Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors